The DOI matches its Crossref record.
Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis
Abstract
Objective. To evaluate the utility of magnetic resonance imaging (MRI) and P‐31 magnetic resonance spectroscopy (MRS) in the longitudinal management of patients with dermatomyositis (DM). Methods. The study group consisted of 11 patients, including 3 children, all of whom had a clinical diagnosis of DM. A control group of 8 subjects was studied simultaneously. MRI included images as well as calculations of T1 and T2 relaxation times. The P‐31 MRS protocol evaluated metabolic status (i.e., inorganic phosphate/phosphocreatine ratios and phosphocreatine and ATP levels) during rest, exercise, and recovery. Results. T2‐weighted images of the thigh muscles showed inflammation even when serum creatine phosphokinase levels were in the normal range. Metabolic abnormalities, which were accentuated with exercise, were found in 10 patients. In some individuals, bioenergetic defects preceded other changes and persisted after resolution of inflammation. In general, clinical impressions correlated with MRI/MRS data. Conclusion. MRI and MRS provide unique data which are quantitative and which cannot be obtained from routine laboratory tests. These MR evaluations appear to be of value in assessing the status of DM patients during treatment with steroids and immuno‐suppressive drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another potential benefit of CrM is the replacement of a deficiency state as seen in genetic, inflammatory [172], and mitochondrial [173], myopathies [174].”
From Creatine monohydrate supplementation for older adults and clinical populations (2025) · cites this paper as [172]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 28
- 10.1056/NEJM197502132920706 · DOI · Paper page
- 10.1056/NEJM197502202920807 · DOI · Paper page
- 10.7326/0003-4819-81-2-182 · DOI
- 10.1016/S0025-6196(12)62170-3 · DOI
- 10.1002/art.1780240107 · DOI
- Carpenter JR, 1977, Survival in polymyositis: corticosteroids and risk factors, J Rheumatol, 4, 207
- 10.1016/0002-9343(86)90036-7 · DOI
- 10.1002/art.1780300212 · DOI
- 10.1093/rheumatology/29.5.371 · DOI
- 10.1148/radiology.177.2.2217788 · DOI
- Fraser DD, 1991, Magnetic resonance imaging in the idiopathic inflammatory myopathies, J Rheumatol, 18, 1693
- 10.1002/art.1780350212 · DOI
- 10.1002/art.1780341217 · DOI
- Ryder N, 1993, Advantages of MRI and P‐31 MR spectroscopy for longitudinal evaluation of prednisone treatment of juvenile dermatomyositis (abstract), Society of Magnetic Resonance in Medicine, 12, 1213
- Schulman M, 1991, MRI and P‐31 MR spectroscopy for evaluation of therapeutic responsiveness of dermatomyositis patients (abstract), J Magn Reson Imaging, 1, 162
- Park JH, 1991, MR imaging and P‐31 spectroscopy for long‐term evaluation of immunosuppressant therapy for inflammatory myopathies (abstract), Radiology, 181, 107
- Kjos BO, 1985, Reproducibility of relaxation times and spin density from routine MR imaging sequence, Am J Neurol Radiol, 6, 271
- Taylor DJ, 1983, Bioenergetics of intact human muscles: a P‐31 nuclear magnetic resonance study, Mol Biol Med, 1, 77
- 10.3109/00365517409082477 · DOI · Paper page
- 10.1212/WNL.37.1.165 · DOI
- 10.1073/pnas.85.23.8780 · DOI · Paper page
- 10.1073/pnas.82.24.8384 · DOI · Paper page
- 10.1016/0190-9622(91)70153-S · DOI · Paper page
- Vital TL, 1992, New classification of myositis confirmed with MRI and P‐31 MR spectroscopy: dermatomyositis and amyopathic dermatomyositis (dermatomyositis siné myositis) (abstract), Society of Magnetic Resonance in Medicine, 11, 2727
- 10.1002/ajmg.1320250408 · DOI
- 10.1148/radiology.170.1.2642336 · DOI
- 10.1016/S0232-1513(85)80051-7 · DOI
- 10.1056/NEJM198105283042206 · DOI · Paper page
Cited by
Creatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub4 · Cited by 169
Clinical Use of Creatine in Neuromuscular and Neurometabolic Disorders
Tarnopolsky, M. A. (2007) · Subcellular Biochemistry · doi:10.1007/978-1-4020-6486-9_10 · Cited by 67
Creatine for treating muscle disorders
Kley, R. A., Vorgerd, M., & Tarnopolsky, M. A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub2 · Cited by 45
Creatine monohydrate supplementation for older adults and clinical populations
Candow, D. G., Ostojic, S. M., Chilibeck, P. D., Longobardi, I., Gualano, B., Tarnopolsky, M. A., Wallimann, T., Moriarty, T., Kreider, R. B., Forbes, S. C., et al. (2025) · Journal of the International Society of Sports Nutrition · doi:10.1080/15502783.2025.2534130 · Cited by 43
Creatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub3 · Cited by 38
Tarnopolsky (1999) · doi:10.1002/(sici)1097-4598(199909)22:9<1228::aid-mus9>3.0.co;2-6
Metadata
- Authors
- Park, J. H., Vital, T. L., Ryder, N. M., Hernanz‐Schulman, M., Leon Partain, C., Price, R. R., & Olsen, N. J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1994-05
- Volume
- 37
- Issue
- 5
- Pages
- 736-746
- ISSN
- 0004-3591
- 1529-0131
- Cited by
- 106
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
